Golimumab for the Treatment of Refractory Behcet's Uveitis

Summary

The aim of this single-center prospective study is to evaluate the efficacy and safety of Golimumab （GOL）, fully humanized anti-tumor necrosis factor (TNF)-α monoclonal antibody, in the treatment of refractory Uveitis of Behçet's disease (BDU), to verify its effects on decreasing the dose of cortical steroids, and to determine whether it can reduce BDU recurrence.

Timeline

Start

2020-02-15

Primary completion

2022-12-15

Completion

2022-12-15

Outcome

Outcome not reported

Stopped (Enrollment): “only one patient enrolled”

Drugs

Indications